Arnaud, L., Hervier, B., Néel, A., Hamidou, M.A., Kahn, J.E., Wechsler, B., Pérez-Pastor, G., Blomberg, B., Fuzibet, J.G., Dubourguet, F., Marinho, A., Magnette, C., Noel, V., Pavic, M., Casper, J., Beucher, A.B., Costedoat-Chalumeau, N., Aaron, L., Salvatierra, J., Graux, C., Cacoub, P., Delcey, V., Dechant, C., Bindi, P., Herbaut, C., Graziani, G., Amoura, Z. and Haroche, J. (2011) CNS Involvement and Treatment with Interferon-α Are Independent Prognostic Factors in Erdheim-Chester disease: A Multicenter Survival Analysis of 53 Patients. Blood, 117, 2778-2782.
https://doi.org/10.1182/blood-2010-06-294108

has been cited by the following article:

• TITLE: Thirty-Four Months Control of Frail Patient with Multisystemic Affection Proved Erdheim Chester Disease: A Case Report

  AUTHORS: Emad Mohsen Barsoum, Fiby Samir Boules, May Gamal Ashour, Mohsen Samy Barsoum

  KEYWORDS: Erdheim-Chester Disease, Histiocytoses, Non-Langerhans Cell Histiocytoses

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.12, December 13, 2021

  ABSTRACT: Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis characterized by multisystemic involvement. We report a case of a 51-year-old male patient treated with pegylated IFN-α in a monthly schedule with low-dose prednisolone and achieved 34 months of control with minimal side effects.